title: Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Fusco
authors.forename: Claudia
authors.initials: C
authors.lastname: Galassi
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
authors.forename: Libero
authors.initials: L
authors.lastname: Ciuffreda
authors.forename: Cinzia
authors.initials: C
authors.lastname: Ortega
authors.forename: Giovannino
authors.initials: G
authors.lastname: Ciccone
authors.forename: Alberto
authors.initials: A
authors.lastname: Angeli
authors.forename: Oscar
authors.initials: O
authors.lastname: Bertetto
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology; D053245:RANK Ligand / Q000009:adverse effects*; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; D000069448:Denosumab; D000077211:Zoledronic Acid